1. Home
  2. MRKR vs NTWK Comparison

MRKR vs NTWK Comparison

Compare MRKR & NTWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • NTWK
  • Stock Information
  • Founded
  • MRKR N/A
  • NTWK 1997
  • Country
  • MRKR United States
  • NTWK United States
  • Employees
  • MRKR N/A
  • NTWK N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • NTWK Computer Software: Prepackaged Software
  • Sector
  • MRKR Health Care
  • NTWK Technology
  • Exchange
  • MRKR Nasdaq
  • NTWK Nasdaq
  • Market Cap
  • MRKR 35.8M
  • NTWK 31.1M
  • IPO Year
  • MRKR N/A
  • NTWK 1998
  • Fundamental
  • Price
  • MRKR $3.10
  • NTWK $2.68
  • Analyst Decision
  • MRKR Strong Buy
  • NTWK
  • Analyst Count
  • MRKR 1
  • NTWK 0
  • Target Price
  • MRKR $19.00
  • NTWK N/A
  • AVG Volume (30 Days)
  • MRKR 26.1K
  • NTWK 26.4K
  • Earning Date
  • MRKR 11-14-2024
  • NTWK 11-13-2024
  • Dividend Yield
  • MRKR N/A
  • NTWK N/A
  • EPS Growth
  • MRKR N/A
  • NTWK N/A
  • EPS
  • MRKR N/A
  • NTWK 0.06
  • Revenue
  • MRKR $5,395,849.00
  • NTWK $61,749,408.00
  • Revenue This Year
  • MRKR $35.94
  • NTWK N/A
  • Revenue Next Year
  • MRKR N/A
  • NTWK N/A
  • P/E Ratio
  • MRKR N/A
  • NTWK $42.00
  • Revenue Growth
  • MRKR 79.04
  • NTWK 14.50
  • 52 Week Low
  • MRKR $2.44
  • NTWK $1.94
  • 52 Week High
  • MRKR $6.16
  • NTWK $3.34
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 42.91
  • NTWK 39.11
  • Support Level
  • MRKR $2.91
  • NTWK $2.48
  • Resistance Level
  • MRKR $3.25
  • NTWK $3.23
  • Average True Range (ATR)
  • MRKR 0.38
  • NTWK 0.15
  • MACD
  • MRKR -0.11
  • NTWK -0.04
  • Stochastic Oscillator
  • MRKR 17.72
  • NTWK 26.67

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About NTWK NetSol Technologies Inc. Common Stock

NETSOL Technologies Inc is involved in providing information technology and enterprise software solutions. Its products and services include NFS Ascent, NFS Digital, Leasepak Cloud, Business consultancy, and information security services among others. The firm has North America, Europe, and Asia-Pacific segments, of which the majority of the revenue is derived from Asia-Pacific. It derives revenue from licensing, customization, enhancements, and maintenance of its financial applications. The company promotes and sells its products under the Netsol financial suite.

Share on Social Networks: